Regulation of αKlotho

Julia E. Vogt, Michael FöllerCellular 2025 · DOI

TL;DR

$\alpha$Klotho is a multi-functional "longevity protein" that acts as both a critical gatekeeper for mineral metabolism and a protective hormone against cellular aging. This comprehensive review synthesizes how various factors—ranging from Vitamin D and exercise to inflammation and specific drugs—modulate $\alpha$Klotho levels, offering a roadmap for its use as a biomarker and therapeutic target in chronic kidney and cardiovascular diseases.

What Problem Does This Paper Address?

Since its discovery in 1997, $\alpha$Klotho (named after the Greek goddess Klotho, who spins the thread of life) has been recognized as a potent anti-aging factor. However, its regulation is incredibly complex. It exists in two primary forms: a membrane-bound version that acts as a mandatory co-receptor for Fibroblast Growth Factor 23 (FGF23) to regulate phosphate levels, and a soluble version (sKL) that circulates in the blood as a hormone.

The core challenge addressed by this paper is the "vicious cycle" seen in chronic kidney disease (CKD) and cardiovascular disease (CVD). In these conditions, $\alpha$Klotho levels drop precipitously, leading to mineral imbalances, vascular calcification, and heart failure. By summarizing the myriad of factors that upregulate or downregulate this protein, the authors aim to identify how we might intervene to restore $\alpha$Klotho levels and slow the progression of age-related diseases.

Methods

As a review article, this paper does not present new experimental data. Instead, it performs a systematic synthesis of over 120 primary research studies. The authors categorize regulators of $\alpha$Klotho into three distinct tables based on:

  1. Transmembrane $\alpha$Klotho in the kidney (the primary site of expression).
  2. $\alpha$Klotho in extrarenal tissues (brain, heart, bone, etc.).
  3. Soluble and secreted $\alpha$Klotho (circulating forms).

The paper specifically looks at the molecular signaling pathways (like TGF-$\beta$, NF$\kappa$B, and Wnt) that mediate these regulatory effects.

Datasets

Not discussed in the paper. As a review, it draws upon previously published datasets from various mouse models (notably the kl/kl mouse strain), cell culture experiments (HK2, MDCK lines), and human clinical observations.

Key Insights and Ideas

  • The Dual-Identity Protein: $\alpha$Klotho isn't just one thing. While the membrane form is tied to phosphate excretion, the soluble form (sKL) acts independently to protect the heart and blood vessels by inhibiting oxidative stress and specific calcium channels (TRPC6).
  • The "Shedding" Mechanism: Soluble Klotho is often created when enzymes like ADAM10 and ADAM17 "clip" the protein off the cell membrane. Interestingly, insulin stimulates this "shedding" process, linking metabolic health directly to circulating anti-aging factors.
  • Early Warning System: The paper highlights that a decrease in $\alpha$Klotho and a corresponding rise in FGF23 are among the earliest detectable biomarkers for CKD, appearing long before traditional markers like serum creatinine change.
  • Lifestyle as a Regulator: Beyond hormones and drugs, the review notes that lifestyle factors like aerobic exercise and adequate sleep are associated with higher levels of soluble $\alpha$Klotho, while high-phosphate diets and dehydration suppress it.

Key Results

The review provides a "cheat sheet" for $\alpha$Klotho modulation:

  • Upregulators: Vitamin D (1,25D), Resveratrol, Statins, PPAR$\gamma$ agonists, and aerobic exercise.
  • Downregulators: Inflammation (TNF$\alpha$), oxidative stress (ROS), high phosphate intake, albuminuria (protein in urine), and uremic toxins like indoxyl sulfate.
  • Pathophysiological Impact: In CKD, the loss of $\alpha$Klotho allows FGF23 to bind to receptors on the heart (FGFR4) without its usual "brake," directly inducing left ventricular hypertrophy (thickening of the heart muscle).
  • Therapeutic Potential: Exogenous administration of Klotho protein has shown promise in animal models for reducing renal fibrosis and acting as a tumor suppressor in various cancers by inhibiting Wnt and IGF-1 signaling.

Limitations and Future Work

  • The Missing Receptor: Despite its known hormonal effects, a specific high-affinity receptor for soluble $\alpha$Klotho has yet to be identified. It currently appears to interact with "lipid rafts" on cell membranes, but the exact mechanism remains elusive.
  • Animal vs. Human Translation: Much of the regulatory data is derived from rodent models. The authors note that more human clinical trials are needed to confirm if the pharmacological interventions that boost Klotho in mice will have the same longevity-promoting effects in humans.
  • Diagnostic Standardization: While $\alpha$Klotho is a promising biomarker, the field lacks standardized assays for measuring its different forms in clinical settings.

Summary updated

Abstract

Since its discovery in 1997, αKlotho has gained a lot of attention due to its powerful anti-aging and health-promoting properties. It exists as a membrane-bound protein or as a soluble factor. Membrane-bound αKlotho is an essential cofactor for fibroblast growth factor 23 (FGF23), thereby being involved in the regulation of renal phosphate and vitamin D metabolism. Soluble αKlotho (sKL) is present in different body fluids and exerts hormone-like effects. Through the αKlotho-FGF23 signaling axis, FGF23 regulates phosphate excretion by downregulating Na+-dependent phosphate transporter (NaPi-2a). In addition, this axis suppresses expression of 1α-hydroxylase, thereby reducing active vitamin D (calcitriol) serum concentration. Disruptions of this axis lead to deranged mineral metabolism. Low levels of αKlotho and elevated FGF23 are early biomarkers for different diseases, including chronic kidney disease (CKD) and cardiovascular diseases (CVD). In CKD, decreased renal αKlotho expression and enhanced FGF23 production contribute to worsening kidney function. Activated transforming growth factor b1 (TGF-b1) signaling, promoting renal fibrosis, contributes to the pathophysiology. Moreover, FGF23 directly induces left ventricular hypertrophy (LVH) through FGF receptor-induced calcineurin/nuclear factor of activated T cells (NFAT) signaling in CKD. Our review aims to comprehensively summarize the regulation and function of αKlotho, highlighting its central role in maintaining mineral metabolism and its therapeutic potential in age-related and chronic diseases.
BibTeX
@inproceedings{vogt2025regulation,
  author = {Julia E. Vogt and Michael Föller},
  title = {{Regulation of αKlotho}},
  booktitle = {Cellular},
  year = {2025},
  doi = {10.33594/000000797},
}
Figure